Mizolastine

證據等級: L5

預測適應症: 10 個

Mizolastine: From H1-Antihistamine Use to Acute Intermittent Porphyria

One-Sentence Summary

Mizolastine is a second-generation, peripherally-selective H1-antihistamine; no marketing authorisation or approved-indication text is currently recorded for it in this evidence pack, and the drug is not currently marketed in the UK. The TxGNN model predicts it may be effective for Acute Intermittent Porphyria, with a prediction score of 99.76%, but zero clinical trials and zero publications currently support this direction — the signal rests entirely on the knowledge-graph model.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack — no UK marketing authorisation is on file (mechanistically characterised only as a second-generation H1-antihistamine)
Predicted New Indication	Acute Intermittent Porphyria
TxGNN Prediction Score	99.76%
Evidence Level	L5
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on the information that is available, Mizolastine is a second-generation H1-receptor antagonist with low anticholinergic activity and poor blood–brain-barrier penetration — a peripherally-selective antihistamine rather than a first-generation, centrally-active agent.

Acute intermittent porphyria is a metabolic disorder of the haem biosynthesis pathway (driven by ALA synthase / porphobilinogen deaminase activity), and there is no established pharmacological pathway connecting H1-receptor antagonism to haem metabolism. If anything, some antihistamines are handled cautiously in porphyria because of hepatic metabolic load, which represents a potential precipitating risk rather than a therapeutic rationale.

Because the original MOA record is a data gap, this mechanistic link cannot be independently verified. It is also notable that Mizolastine’s other top nine TxGNN predictions in this pack cluster heavily around movement/tic disorders (e.g. psychogenic movement disorders, tardive-type dyskinesia, chronic tic disorder, extrapyramidal disease) with similarly weak or absent mechanistic support — a pattern consistent with a knowledge-graph embedding artefact (disease-ontology or shared-node clustering) rather than a genuine drug–disease biological signal. This context should temper confidence in the acute-intermittent-porphyria prediction specifically.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Note: formal TFDA/MHRA warning and contraindication data for Mizolastine could not be retrieved for this evidence pack (Blocking-severity data gap) and safety review has not progressed past initial screening. Given the predicted indication is a porphyria-related condition, any future evaluation should specifically check the drug’s classification in the Drugs Database for Acute Porphyria (Welsh Medicines Information Centre / European Porphyria Network), as inappropriate drug exposure can precipitate acute attacks in this patient group.

Conclusion and Next Steps

Decision: Hold

Rationale:

The prediction is supported by TxGNN model output alone (Evidence Level L5, decision stage S0) — there are no clinical trials, no literature, and no verified mechanistic pathway linking H1-antihistamine activity to acute intermittent porphyria.
Mizolastine currently has no UK marketing authorisation on record, and core safety data (SmPC warnings/contraindications) needed for even a preliminary safety screen is missing (Blocking-severity data gap).

To proceed, the following is needed:

Confirmed mechanism of action data for Mizolastine (High-severity data gap, DG002)
TFDA/MHRA-sourced SmPC warnings and contraindications to enable a baseline safety assessment (Blocking-severity data gap, DG001)
Confirmation of Mizolastine’s status in the Drugs Database for Acute Porphyria before any porphyria-related use is considered
Preclinical or mechanistic studies specifically probing any relationship between H1-receptor antagonism and haem biosynthesis, to test whether this prediction reflects a real biological signal or a knowledge-graph artefact
Ongoing monitoring for any emerging clinical trial or literature evidence, given none currently exists
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.